- Home
- SLGB vs NRSN Comparison
SLGB vs NRSN Comparison
Compare SLGB & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGB | NRSN |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | Hong Kong | Israel |
| Employees | N/A | 16 |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.1M | 26.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SLGB | NRSN |
|---|---|---|
| Price | $0.60 | $0.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 83.8K | ★ 146.6K |
| Earning Date | 05-16-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | $29.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.63 |
| 52 Week High | $6.02 | $2.60 |
Technical Indicators
Market Signals| Indicator | SLGB | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 37.39 | 53.24 |
| Support Level | N/A | $0.67 |
| Resistance Level | $1.20 | $0.86 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 26.99 | 48.19 |
Price Performance
Historical ComparisonAbout SLGB Smart Logistics Global Limited Ordinary Shares
Smart Logistics Global Ltd is a contract logistics solution provider in the PRC focusing on industrial raw materials line-haul transportation business. the group focuses on the logistics digital ecosystem through innovation, digital analytics, and infrastructure establishment.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.